Physician profile
Catherine Oneill
NPI 1760801369
$4,109.14
in general payments reported to CMS, 2019-2025
25 companies · $959 in 2025
The $959 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $275 · 2023: $1,103 · 2024: $1,394 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,456.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,200.42 | 2021-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $528.99 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $424.63 | 2021-2025 | Spravato |
| Abbvie INC. | $422.27 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $373.84 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $198.36 | 2023-2024 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $177.02 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $161.80 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $124.10 | 2022-2024 | Trintellix |
| Axsome Therapeutics, INC. | $98.29 | 2022-2025 | Auvelity |
| Harmony Biosciences LLC | $69.69 | 2023-2024 | Wakix |
| Sunovion Pharmaceuticals INC. | $47.78 | 2021 | |
| Csl Behring | $42.56 | 2021 | |
| Bausch Health US, LLC | $39.40 | 2022-2024 | Aplenzin |
| Acadia Pharmaceuticals INC | $37.55 | 2025 | Nuplazid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $25.23 | 2025 | |
| Tempus Ai, INC | $18.58 | 2024 | Tempus Pixel |
| Neurelis, INC. | $17.80 | 2023 | Valtoco |
| Almatica Pharma LLC | $16.56 | 2025 | Loreev Xr |
| Ge Healthcare | $16.27 | 2024 | |
| Jazz Pharmaceuticals INC. | $14.85 | 2021 | |
| Abbott Laboratories | $14.10 | 2024 | Eterna |
| Supernus Pharmaceuticals, INC. | $13.73 | 2023 | Qelbree |
| Noven Therapeutics, LLC | $13.56 | 2025 | Xelstrym |
| Eisai INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Oneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.